Merck Sharp & Dohme Ltd Competitors

iCeutica is a privately held pharmaceutical research and development company located in King of Prussia, PA. iCeutica applies our proprietary SoluMatrix™ Fine Particle Technology to both approved and development stage drug compounds, creating new branded medicines independently and in collaboration with selected pharmaceutical partners. The resulting products provide meaningful clinical benefits for patients and have clearly defined pathways to regulatory and commercial success. There are currently four FDA approved and marketed prescription drugs that use SoluMatrix Fine Particle Technology (pain drugs Zorvolex™, Tivorbex™, and Vivlodex™ and prostate cancer drug Yonsa®). In addition, iCeutica and our partners have several pipeline products in various stages of development.

Matrix Biomed, Inc. is a biopharmaceutical company focused on delivering gene-based therapeutics. Gene-based therapeutics are directed to address both the dysregulation of multiple genes as well as their interactions in gene regulatory networks. Matrix Biomed, Inc. creates extensive gene regulatory networks and gene co-expression networks that are able to identify correlations between genes indicating which genes are active or inactive simultaneously. By redefining human diseases within these networks, Matrix Biomed, Inc. gains a broader understanding of the disease mechanism and drug-disease mechanism allowing Matrix Biomed, Inc. to accelerate the discovery and identification of novel therapeutic approaches to revert a disease state to a healthy state. Matrix Biomed, Inc. departs with standard industry practices by extensively exploring the functional connection between drugs, genes, and diseases. By departing with these practices, Matrix Biomed, Inc.'s objective is to increase the relatively low rate at which novel drug candidates are translated into effective clinical therapies. With an average development timeframe of 15 years, a cost of over 1 billion U.S., and a success rate of less than ten percent for discovery of a single novel drug, the pharmaceutical industry is in dire need of reformed models and practices. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state. Currently, Matrix Biomed, Inc. gene-based therapeutics are directed to therapies and drug products to make cancer treatment more manageable and successful through the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy. Radiation and chemotherapy-induced toxicity remains one of the most significant barriers to the delivery of curative doses of cancer chemotherapy. Particularly troubling are the ...

ZeneXa Limited is a UK based company which provides IT services and IT consultancy across multiple platforms and areas of expertise. Our small, but dedicated team is always ready to deliver high quality services for small to medium size businesses and companies.